Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly’s Phase 3 RELAY study of Cyramza showed improvement in the time patients lived without their cancer growing or spreading after starting treatment, the company said Tuesday.
Pfizer got approval for Trazimera n USA for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 adenocarcinoma.
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Bexion’s Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites.
Taiho Oncology got aproval to have its Lonsurf as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in the United States.
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.
Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.
Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.